Zytiga - latest news (June 2, 2023)

AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer


The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD’s Lynparza (olaparib), with ...

FDA OKs Olaparib-Abiraterone for Metastatic Prostate Cancer


The FDA has approved the PARP inhibitor olaparib (Lynparza) in combination with abiraterone (Zytiga) for BRCA-mutated ...

Lockerbie bomber survived 3 more years after getting cancer drug denied to NHS


Respected oncologist Professor Karol Sikora (inset) explains how a cancer drug initially denied to NHS patients, extended the ...

FDA ap­proves As­traZeneca's Lyn­parza com­bo for adults with BR­CA-mu­tat­ed prostate can­cer


In April, an FDA adcomm gave the thumbs up to AstraZeneca’s blockbuster PARP inhibitor Lynparza label expansion into prostate ...

As­traZeneca gives up on late-stage IL-23 drug due to tri­al de­lays, com­pet­i­tive land­scape


AstraZeneca is shelving an IL-23 antibody that’s been through a winding journey around pharma — including stops at Amgen and ...

FDA clears narrow use of Lynparza in early prostate cancer, continuing ‘shift’ on PARP drugs


The new approval covers earlier use, alongside one of those treatments — Zytiga — and a steroid. Still, treatment isn’t cleared for prostate cancer broadly, as the developers had originally hoped. The ...

China’s 4+7 drug procurement policy and its impact on the pharma industry


Therefore, it is important to follow any changes to China’s pharma industry, since the impact could be global. Certainly, 4+7 ...

Certain Toxic Effects Higher With Newer Prostate Cancer Therapies


Currently, there are four second-generation AAs approved by the FDA for metastatic hormone-sensitive prostate cancer: abiraterone (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), and ...